Loading...
•
Dec 31, 2024
ADMA Biologics Q4 2024 Earnings Report
Estimated Revenue:$115M
+59.2% YoY
Estimated EPS:$0.164
+700.0% YoY
Key Takeaways
ADMA Biologics achieved $117.5 million in revenue for Q4 2024, reflecting a 59% year-over-year increase. Gross profit more than doubled to $63.3 million, with gross margin improving to 54.0%. The company reported GAAP net income of $111.9 million, significantly reversing a prior-year net loss. Adjusted EBITDA more than doubled to $48.3 million. Strong operational cash flow further strengthened the balance sheet, positioning the company for continued growth.
Revenue surged 59% YoY to $117.5 million, driven by increased IG sales.
Gross margin expanded to 54.0% from 42.1% YoY.
Net income of $111.9 million, reversing a loss of $17.6 million last year.
Adjusted EBITDA more than doubled to $48.3 million.
ADMA Biologics
ADMA Biologics
Forward Guidance
ADMA expects continued revenue growth, supported by strong demand for ASCENIV and operational efficiencies. The company aims to surpass $490 million in revenue for FY 2025 and exceed $1 billion annually before 2030.
Positive Outlook
- Revenue projected to exceed $490 million in FY 2025.
- Strong demand for ASCENIV expected to drive market share growth.
- Yield enhancement production approval anticipated by mid-2025.
- Expansion of plasma supply agreements strengthens long-term growth.
- Debt reduction efforts improving financial flexibility.
Challenges Ahead
- Potential regulatory delays for yield enhancement production approval.
- Macroeconomic conditions could impact patient affordability and insurance reimbursements.
- Operational scaling challenges as production volumes increase.
- Increased competition in the immunoglobulin market.
- Stock-based compensation expenses may impact profitability.